{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:38:20Z","timestamp":1793993900141,"version":"4.8.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.peptides.2026.171480","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:42:46Z","timestamp":1771918966000},"page":"171480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes"],"prefix":"10.1016","volume":"196","author":[{"given":"Clifford J.","family":"Bailey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Flatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2026.171480_bib1","unstructured":"Centers for Disease Control and Prevention. Adult obesity facts 2024, \u3008https:\/\/www.cdc.gov\/obesity\/adult-obesity-facts\/index.htm\u3009 (accessed 7 December 2025)."},{"key":"10.1016\/j.peptides.2026.171480_bib2","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report 2024 \u3008https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html\u3009 (accessed 7 Dec. 2025)."},{"key":"10.1016\/j.peptides.2026.171480_bib3","first-page":"851","article-title":"Costs of obesity, obesity-related complications, and weight loss in the United States: a systematic literature review","volume":"31","author":"Bjornson","year":"2025","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.peptides.2026.171480_bib4","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1007\/s00125-023-05929-0","article-title":"Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy","volume":"66","author":"Tschop","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2026.171480_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2025.171380","article-title":"Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities","volume":"187","author":"Bailey","year":"2025","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2026.171480_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00125-025-06581-6","article-title":"Pharmacological therapies for type 2 diabetes: future approaches","volume":"69","author":"Bailey","year":"2026","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2026.171480_bib7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1152\/physrev.00042.2009","article-title":"Islet amyloid polypeptide, islet amyloid, and diabetes mellitus","volume":"91","author":"Westermark","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.peptides.2026.171480_bib8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.peptides.2026.171480_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177593","article-title":"The protective effect of amylin in type 2 diabetes: yes or no","volume":"996","author":"Alanazi","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.peptides.2026.171480_bib10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s13300-025-01733-8","article-title":"Amylin: from mode of action to future clinical potential in diabetes and obesity","volume":"16","author":"Vol\u010dan\u0161ek","year":"2025","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.peptides.2026.171480_bib11","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/d41573-025-00183-y","article-title":"Lilly\u2019s tirzepatide and Novo Nordisk\u2019s semaglutide vie for top drug spot","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.peptides.2026.171480_bib12","article-title":"Recent achievements and future directions of anti-obesity medications","volume":"47","author":"Grandl","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.peptides.2026.171480_bib13","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3390\/ijms25031517","article-title":"Amylin, another important neuroendocrine hormone for the treatment of diabesity","volume":"25","author":"Er\u017een","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.peptides.2026.171480_bib14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0006-291X(86)90708-4","article-title":"A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas","volume":"140","author":"Westermark","year":"1986","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.peptides.2026.171480_bib15","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1073\/pnas.84.11.3881","article-title":"Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells","volume":"84","author":"Westermark","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.peptides.2026.171480_bib16","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","article-title":"Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients","volume":"84","author":"Cooper","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.peptides.2026.171480_bib17","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.3390\/jcm11082207","article-title":"Mediators of amylin action in metabolic control","volume":"11","author":"Boyle","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.peptides.2026.171480_bib18","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1074\/jbc.M115.713628","article-title":"Calcitonin and amylin receptor peptide interaction mechanisms: insights into peptide-binding modes and allosteric modulation of the calcitonin receptor by receptor activity-modifying proteins","volume":"291","author":"Lee","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"900","key":"10.1016\/j.peptides.2026.171480_bib19","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1126\/scisignal.adt8127","article-title":"Amylin receptor subunit interactions are modulated by agonists and determine signaling","volume":"18","author":"Gostynska","year":"2025","journal-title":"Sci. Signal."},{"key":"10.1016\/j.peptides.2026.171480_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1021\/acsptsci.8b00002","article-title":"Molecular signature for receptor engagement in the metabolic peptide hormone amylin","volume":"1","author":"Bower","year":"2018","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.peptides.2026.171480_bib21","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/bph.13496","article-title":"Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development","volume":"173","author":"Bower","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2026.171480_bib22","first-page":"3","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25","author":"Hay","year":"2017","journal-title":"Br. J. Pharmacol. 175"},{"key":"10.1016\/j.peptides.2026.171480_bib23","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1074\/jbc.M115.713628","article-title":"Calcitonin and amylin receptor peptide interaction mechanisms: insights into peptide-binding modes and allosteric modulation of the calcitonin receptor by receptor activity-modifying proteins","volume":"291","author":"Lee","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"6587","key":"10.1016\/j.peptides.2026.171480_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm9609","article-title":"A structural basis for amylin receptor phenotype","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.peptides.2026.171480_bib25","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2337\/db17-1347","article-title":"Amylin selectively signals to POMC neurons in the arcuate nucleus of the hypothalamus","volume":"67","author":"Lutz","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2026.171480_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170366","article-title":"Amylin brain circuitry","volume":"132","author":"Boccia","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2026.171480_bib27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/j.2040-4603.2020.tb00140.x","article-title":"Systemic and central amylin, amylin receptor signaling, and their physiological and pathophysiological roles in metabolism","volume":"10","author":"Foll","year":"2020","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.peptides.2026.171480_bib28","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cmet.2015.10.012","article-title":"Hypothalamic amylin acts in concert with leptin to regulate food intake","volume":"22","author":"Li","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2026.171480_bib29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/dmrr.263","article-title":"Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity","volume":"18","author":"Mather","year":"2002","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.peptides.2026.171480_bib30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.physbeh.2016.02.034","article-title":"Amylin-mediated control of glycemia, energy balance, and cognition","volume":"162","author":"Mietlicki-Baase","year":"2016","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.peptides.2026.171480_bib31","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1152\/physrev.00066.2017","article-title":"The activity of peptides of the calcitonin family in bone","volume":"99","author":"Naot","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.peptides.2026.171480_bib32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1054-3589(05)52015-5","article-title":"Renal effects","volume":"52","author":"Young","year":"2025","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.peptides.2026.171480_bib33","doi-asserted-by":"crossref","DOI":"10.1063\/1.4798460","article-title":"\u03b1-helix to \u03b2-hairpin transition of human amylin monomer","volume":"138","author":"Singh","year":"2013","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.peptides.2026.171480_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134091","article-title":"Secondary structure of rat and human amylin across force fields","volume":"10","author":"Hoffmann","year":"2015","journal-title":"PLOS One"},{"key":"10.1016\/j.peptides.2026.171480_bib35","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.bpj.2013.07.029","article-title":"Effect of proline mutations on the monomer conformations of amylin","volume":"105","author":"Chiu","year":"2013","journal-title":"Biophys. J."},{"key":"10.1016\/j.peptides.2026.171480_bib36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1054-3589(05)52018-0","article-title":"Clinical studies","volume":"52","author":"Young","year":"2005","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.peptides.2026.171480_bib37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/14746514050050030701","article-title":"Amylin analogue as an antidiabetic agent","volume":"5","author":"Day","year":"2005","journal-title":"Brit. J. Diab. Vasc. Dis."},{"key":"10.1016\/j.peptides.2026.171480_bib38","unstructured":"Pramlintide. Product label 2014. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021332s007_S016.pdf\u3009."},{"key":"10.1016\/j.peptides.2026.171480_bib39","article-title":"Ultra-fast insulin-pramlintide co-formulation for improved glucose management in diabetic rats","volume":"8","author":"Maikawa","year":"2021","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.peptides.2026.171480_bib40","doi-asserted-by":"crossref","first-page":"66504","DOI":"10.18632\/oncotarget.16008","article-title":"Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis","volume":"8","author":"Qiao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.peptides.2026.171480_bib41","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.4158\/EP13477.OR","article-title":"Effects of pramlintide in patients with Type 2 diabetes mellitus: an analysis using daily insulin dose tertiles","volume":"20","author":"Herrmann","year":"2014","journal-title":"Endoc. Pract."},{"key":"10.1016\/j.peptides.2026.171480_bib42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1586\/eem.12.50","article-title":"Pramlintide: profile of an amylin analog","volume":"7","author":"Lebovitz","year":"2012","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2026.171480_bib43","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/14656566.2011.581663","article-title":"Pramlintide and the treatment of diabetes: a review of the data since its introduction","volume":"12","author":"Younk","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.peptides.2026.171480_bib44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/vhrm.2006.2.3.203","article-title":"Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes","volume":"2","author":"Pullman","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.peptides.2026.171480_bib45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40842-016-0030-z","article-title":"Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials","volume":"2","author":"Herrmann","year":"2016","journal-title":"Clin. Diabetes Endocrinol."},{"key":"10.1016\/j.peptides.2026.171480_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1210\/en.2013-1658","article-title":"Activity of pramlintide, rat and human amylin but not A\u03b21-42 at human amylin receptors","volume":"155","author":"Gingell","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2026.171480_bib47","unstructured":"Pramlintide, IUPHAR\/BPS Guide to pharmacology. \u3008https:\/\/www.guidetopharmacology.org\/GRAC\/LigandDisplayForward?tab=biology&ligandId=7482\u3009 (accessed 20 Dec 2025)."},{"key":"10.1016\/j.peptides.2026.171480_bib48","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/ijo.2009.238","article-title":"Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight","volume":"34","author":"Mack","year":"2010","journal-title":"Int. J. Obes. (Lond. )"},{"key":"10.1016\/j.peptides.2026.171480_bib49","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1463-1326.2011.01465.x","article-title":"Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide","volume":"13","author":"Mack","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2026.171480_bib50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1021\/acschembio.5c00685","article-title":"Probing the effect of alpha-helical stapling Strategies on the inhibition of peptide aggregation and amyloid cytotoxicity","volume":"21","author":"Babych","year":"2026","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.peptides.2026.171480_bib51","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1038\/s41467-025-58680-y","article-title":"Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors","volume":"16","author":"Cao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2026.171480_bib52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/molpharm.123.000865","article-title":"Development of a novel assay for direct assessment of selective amylin receptor activation reveals novel differences in behaviour of selective and nonselective peptide agonists","volume":"105","author":"Keov","year":"2024","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.peptides.2026.171480_bib53","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1530\/EJE-21-1261","article-title":"Therapy of endocrine disease: amylin and calcitonin - physiology and pharmacology","volume":"186","author":"Mathiesen","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.peptides.2026.171480_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114969","article-title":"Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss","volume":"164","author":"Larsen","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.peptides.2026.171480_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113842","article-title":"Does receptor balance matter? - comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models","volume":"156","author":"Larsen","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.peptides.2026.171480_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.617400","article-title":"Amylin and calcitonin: potential therapeutic strategies to reduce body weight and liver fat","volume":"11","author":"Mathiesen","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.peptides.2026.171480_bib57","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MED.0000000000000716","article-title":"Long-acting amylin analogues for the management of obesity","volume":"29","author":"Mathiesen","year":"2022","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.peptides.2026.171480_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101109","article-title":"Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases","volume":"46","author":"Sonne","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2026.171480_bib59","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2026.171480_bib60","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2026.171480_bib61","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2026.171480_bib62","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2026.171480_bib63","doi-asserted-by":"crossref","first-page":"26055","DOI":"10.1161\/HYPERTENSIONAHA.125.26055","article-title":"CagriSema reduces blood pressure in adults with overweight or obesity: REDEFINE 1","volume":"83","author":"Verma","year":"2026","journal-title":"Hypertension"},{"issue":"10403","key":"10.1016\/j.peptides.2026.171480_bib64","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2026.171480_bib65","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide\u2013semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2026.171480_bib66","first-page":"15","article-title":"Efficacy and safety of cagrilintide 2.4 mg in adults with overweight\/obesity: data from REDEFINE 1","author":"Garvey","year":"2025","journal-title":"Latebreaking presentation European Association Study Diabetes (EASD) annual meeting"},{"key":"10.1016\/j.peptides.2026.171480_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105862","article-title":"The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats","volume":"118","author":"Kuhre","year":"2025","journal-title":"EBioMedicine"},{"issue":"10499","key":"10.1016\/j.peptides.2026.171480_bib68","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(25)01176-6","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Gasiorek","year":"2025","journal-title":"Lancet"},{"issue":"10499","key":"10.1016\/j.peptides.2026.171480_bib69","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study","volume":"406","author":"Dahl","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2026.171480_bib70","unstructured":"Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1C reduction in type 2 diabetes. News release. Novo Nordisk. November 25, 2025, \u3008https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916463\u3009 (accessed Dec. 1, 2025)."},{"key":"10.1016\/j.peptides.2026.171480_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102271","article-title":"Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept","volume":"102","author":"Briere","year":"2025","journal-title":"Mol. Metab."},{"issue":".1","key":"10.1016\/j.peptides.2026.171480_bib72","article-title":"Eloralintide, a selective, long-acting amylin receptor agonist for obesity - phase 1 proof of concept","volume":"74","author":"Bhattachar","year":"2025","journal-title":"Diabetes"},{"issue":"10520","key":"10.1016\/j.peptides.2026.171480_bib73","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/S0140-6736(25)02155-5","article-title":"Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Billings","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2026.171480_bib74","doi-asserted-by":"crossref","first-page":"23925","DOI":"10.1021\/acs.jmedchem.5c01185","article-title":"Development of petrelintide: a potent, stable, long-acting human amylin analogue","volume":"68","author":"Fischer Munch","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2026.171480_bib75","unstructured":"Zealand Pharma, Petrelintide: Topline data 16-week trial (MAD Part 2). June 20, 2024. \u3008https:\/\/www.zealandpharma.com\/media\/kiioen11\/zealand-pharma_petrelintide-part-2-mad-16-week-trial_conference-call-20-june-2024.pdf\u3009 (accessed 19 Dec. 2025)."},{"key":"10.1016\/j.peptides.2026.171480_bib76","unstructured":"T. Heise, Safety, tolerability, and clinical effects of Petrelintide (ZP8396), a long-acting amylin analog. 2 November 2024 \u3008https:\/\/www.zealandpharma.com\/media\/vrypyzy1\/zealand-pharma-at-obesity-week-2024.pdf\u3009 (accessed 18 Dec. 2025)."},{"key":"10.1016\/j.peptides.2026.171480_bib77","unstructured":"Roche press release 12 Mar 2025. Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity. \u3008https:\/\/www.roche.com\/media\/releases\/med-cor-2025-03-12\u3009, (accessed 18 Dec. 2025)."},{"issue":".1","key":"10.1016\/j.peptides.2026.171480_bib78","first-page":"OP707","article-title":"Characterisation of AZD6234, a novel amylin receptor selective agonist peptide, in rodent models of weight loss and aversion","volume":"68","author":"Hornigold","year":"2025","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2026.171480_bib79","unstructured":"AstraZeneca webinar for investors and analysts. Weight Management Virtual Event. 4 November 2024. \u3008https:\/\/www.astrazeneca.com\/content\/dam\/az\/Investor_Relations\/events\/Weight-Management-Virtual-Event-IR-presentation.pdf\u3009 (accessed 19 Dec. 2025)."},{"issue":".1","key":"10.1016\/j.peptides.2026.171480_bib80","article-title":"MET-233 is an ultra-long-acting amylin receptor agonist","volume":"74","author":"Minnion","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2026.171480_bib81","unstructured":"Metsera press release, June 9, 2025. Topline Phase 1 results for MET-233i. \u3008https:\/\/metsera.com\/pipeline\/\u3009 (accessed 26 Jan 2026)."},{"key":"10.1016\/j.peptides.2026.171480_bib82","unstructured":"Clinical Trials.gov trials with MET-233. https:\/\/clinicaltrials.gov\/study\/NCT07022977 and \u3008https:\/\/clinicaltrials.gov\/study\/NCT06924320\/\u3009 (accessed 26 Jan 2026)."},{"key":"10.1016\/j.peptides.2026.171480_bib83","doi-asserted-by":"crossref","first-page":"11688","DOI":"10.1021\/acs.jmedchem.4c00022","article-title":"NN1213 - a potent, long-acting, and selective analog of human amylin","volume":"67","author":"Dahl","year":"2024","journal-title":"J. Med Chem."},{"issue":".1","key":"10.1016\/j.peptides.2026.171480_bib84","article-title":"The amylin receptor selective agonist NN1213 reduces food intake and body weight in rats without decreasing calcium plasma levels, Free","volume":"74","author":"Ipsen","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2026.171480_bib85","unstructured":"Novo Nordisk R & D Pipeline 2025. \u3008https:\/\/www.novonordisk.com\/science-and-technology\/r-d-pipeline.html\u3009 (accessed 27 Dec. 2025)."},{"key":"10.1016\/j.peptides.2026.171480_bib86","unstructured":"M. Axelsen S., Sidhu, A study in healthy male volunteers to look at the safety and tolerability of the new test medicine GUB014295 and how it is taken up by the body when given as a single dose by injection, \u3008https:\/\/www\u3009. isrctn. com\/ ISRCTN8511 2396 (accessed 21 Jan. 2026)."},{"key":"10.1016\/j.peptides.2026.171480_bib87","unstructured":"Gubra Press Release, 1 Apr 2025. \u3008https:\/\/www.gubra.dk\/mfn_news\/gubra-announces-positive-gubamy-phase-1-interim-mad-results\u3009 (accessed 25 Jan. 2026)."},{"key":"10.1016\/j.peptides.2026.171480_bib88","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bph.13723","article-title":"K. A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference","volume":"174","author":"Gydesen","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2026.171480_bib89","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12902-020-00678-2","article-title":"The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile","volume":"21","author":"Larsen","year":"2021","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.peptides.2026.171480_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114969","article-title":"Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss","volume":"164","author":"Larsen","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"26","key":"10.1016\/j.peptides.2026.171480_bib91","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-024-03361-2","article-title":"The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection - a novel disease-modifying osteoarthritis drug","volume":"2024","author":"Mohamed","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.peptides.2026.171480_bib92","unstructured":"Ascletis Pharma Press release, 12 November 2025. \u3008https:\/\/www.prnewswire.com\/news-releases\/ascletis-announces-co-formulation-of-asc36-once-monthly-next-generation-amylin-receptor-agonist-and-asc35-once-monthly-next-generation-glp-1rgipr-dual-agonist-for-clinical-development-302613458.html\u3009 (accessed 25 Jan 2026)."},{"issue":".1","key":"10.1016\/j.peptides.2026.171480_bib93","article-title":"Novel oral small molecule ACCG-2671 - dual amylin and calcitonin receptor agonist development candidate for obesity therapy","volume":"74","author":"Fang","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2026.171480_bib94","unstructured":"Iktos Press Release 10 Jan 2026, \u3008https:\/\/firstwordpharma.com\/story\/5926849\u3009, (accessed 25 Jan 2026)."},{"key":"10.1016\/j.peptides.2026.171480_bib95","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41574-018-0118-x","article-title":"Emerging1 hormonal-based combination pharmacotherapies for the treatment of metabolic diseases","volume":"15","author":"Clemmensen","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.peptides.2026.171480_bib96","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1042\/bst0110804","article-title":"Small peptides as carriers and targets in human therapy","volume":"11","author":"Ringrose","year":"1983","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.peptides.2026.171480_bib97","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4103\/ijem.ijem_45_24","article-title":"Efficacy and safety of cagrilintide alone and in combination with semaglutide (CagriSema) as anti-obesity medications: a systematic review and meta-analysis","volume":"28","author":"Dutta","year":"2024","journal-title":"Indian J. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2026.171480_bib98","doi-asserted-by":"crossref","first-page":"R697","DOI":"10.1152\/ajpregu.00338.2020","article-title":"Amylin antibodies frequently display cross-reactivity with CGRP: characterization of eight amylin antibodies","volume":"320","author":"Rees","year":"2021","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.peptides.2026.171480_bib99","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/dom.70141","article-title":"Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study","volume":"28","author":"Alissou","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2026.171480_bib100","first-page":"216","article-title":"Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: a systematic review and meta-analysis","volume":"179","author":"Ko","year":"2026","journal-title":"Intern. Med."},{"key":"10.1016\/j.peptides.2026.171480_bib101","doi-asserted-by":"crossref","first-page":"424","DOI":"10.14309\/ajg.0000000000003525","article-title":"Glucagon-like peptide-1 receptor agonists use does not increase the risk for acute pancreatitis and is associated with lower complications in patients with Type 2 diabetes who develop acute pancreatitis: a multicenter analysis","volume":"121","author":"Nieto","year":"2026","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.peptides.2026.171480_bib102","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s00125-016-3906-7","article-title":"Renaissance of leptin for obesity therapy","volume":"59","author":"Quarta","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2026.171480_bib103","doi-asserted-by":"crossref","first-page":"56494","DOI":"10.1016\/j.metabol.2026.156494","article-title":"Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond","volume":"177","author":"Muzurovi\u0107","year":"2026","journal-title":"Metabolism"},{"key":"10.1016\/j.peptides.2026.171480_bib104","doi-asserted-by":"crossref","first-page":"E529","DOI":"10.1152\/ajpendo.00245.2023","article-title":"Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats","volume":"325","author":"Melander","year":"2023","journal-title":"Am. J. Physiol. Endocrinol. Metab."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978126000173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978126000173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:30:33Z","timestamp":1773912633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978126000173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":104,"alternative-id":["S0196978126000173"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2026.171480","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2026.171480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"171480"}}